Reference

1. Langner M, Kozubek A. Pharmacokinetic modulation with particulate drug formulations. Nanocarrier Technologies: Frontiers of Nanotherapy. 2006:113-38.
2. Carlson TJ, Fisher MB. Recent advances in high throughput screening for ADME properties. Combinatorial chemistry & high throughput screening. 2008 Mar 1;11(3):258-64.
3. Bernardo PH, Tong JC. In silico design of small molecules. Chemical Genomics and Proteomics: Reviews and Protocols. 2012:25-31.
4. Kodadek T. The rise, fall and reinvention of combinatorial chemistry. Chemical communications. 2011;47(35):9757-63.
5. Jones HM, Mayawala K, Poulin P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. The AAPS journal. 2013 Apr;15(2):377-87.
6. Brater DC. Anti-inflammatory agents and renal function. InSeminars in arthritis and rheumatism 2002 Dec 1 (Vol. 32, No. 3, pp. 33-42). WB Saunders.
7. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (London, England). 2013 May 30;382(9894):769-79.
8. Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiology and drug safety. 2010 Jul;19(7):745-51.
9. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose–response relationships between individual nonaspirin nonsteroidal anti?inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta?analysis based on individual patient data. British journal of clinical pharmacology. 2002 Sep;54(3):320-6.
10. Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S, Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug safety. 2012 Dec;35:1127-46.
11. Salvo F, Fourrier?Réglat A, Bazin F, Robinson P, Riera?Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A, investigators of the Safety of Non?Steroidal Anti?Inflammatory Drugs: The SOS Project. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta?analyses of randomized clinical trials. Clinical Pharmacology & Therapeutics. 2011 Jun;89(6):855-66.
12. Salvo F, Fourrier?Réglat A, Bazin F, Robinson P, Riera?Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A, investigators of the Safety of Non?Steroidal Anti?Inflammatory Drugs: The SOS Project. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta?analyses of randomized clinical trials. Clinical Pharmacology & Therapeutics. 2011 Jun;89(6):855-66.
13. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS medicine. 2011 Sep 27;8(9):e1001098.
14. Altman R, Bosch B, Brune K, Patrignani P, Young C. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015 May;75:859-77.
15. Moreno MM, Garidel P, Suwalsky M, Howe J, Brandenburg K. The membrane-activity of Ibuprofen, Diclofenac, and Naproxen: A physico-chemical study with lecithin phospholipids. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2009 Jun 1;1788(6):1296-303.
16.  Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. Journal of pharmacy & pharmaceutical sciences. 2008 Sep 20;11(2):81s-110s.
17. Maclagan T. The treatment of rheumatism by salicin and salicylic acid. British medical journal. 1876 May 5;1(803):627.
18. Stricker S. Über die Resultate der Behandlung der Polyarthritis rheumatica mit Salicylsäure. Berl Klin Wochenschr. 1876;13:1-2.
19.  Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000;321(7276):1591–4.
20.  Brune K, Hinz B. The discovery and development of antiinflammatory drugs. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2004 Aug;50(8):2391-9.
21. . Domenjoz R. The pharmacology of phenylbutazone analogues. Annals of the New York Academy of Sciences. 1960 Mar;86(1):263-91.
22. Madhusudan Rao Y, Veni JK, Jayasagar G. Formulation and evaluation of diclofenac sodium using hydrophilic matrices. Drug development and industrial pharmacy. 2001 Jan 1;27(8):759-66.
23. Badwaik H, Tripathi DK. In vitro evaluation of commercially available enteric coated tablet containing diclofenac sodium. inflammation. 2012;2:3.
24. Chhater S, Rajesh K, Kshitij A, Nema RK. Development and evaluation of enteric coated tablet containing diclofenac sodium. International journal of pharmaceutical sciences and nanotechnology. 2009;2:443-9.
25. Badwaik H, Tripathi DK. In vitro evaluation of commercially available enteric coated tablet containing diclofenac sodium. inflammation. 2012;2:3..
26.  Pharmacopoeia I. Controller of publications. New Delhi. 1996;2:764.
27.  Zaid AN, Qaddomi A. Development and stability evaluation of enteric coated Diclofenac sodium tablets using Sureteric. Pakistan journal of pharmaceutical sciences. 2012 Jan 1;25(1).
28. Malviya V, Thakur Y, Gudadhe SS, Tawar M. Formulation and evaluation of natural gum based fast dissolving tablet of Meclizine hydrochloride by using 3 factorial design 2. Asian Journal of Pharmacy and Pharmacology. 2020;6(2):94-100.